Medication Guide App

Orexigen Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society

 

 

SAN DIEGO, Oct. 4 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced the schedule of its upcoming Contrave® (naltrexone sustained release (SR)/bupropion SR) presentations taking place at the 28th Annual Scientific Meeting of The Obesity Society. This meeting will be held at the San Diego Convention Center, October 8-12, 2010.


Sunday, October 10:  Embargo Lifts October 10 at 12:30 p.m. PT

 

Poster Presentation
Abstract: 478-P
Presenter: Louis Aronne, M.D., New York Weill Cornell-Columbia Presbyterian Hospital, New York, NY
Title: "Naltrexone SR/Bupropion SR Combination Therapy Reduced Weight and Improved Markers of Cardiometabolic Risk: A Pooled Analysis of Two Phase 3, 56-Week, Double-Blind, Placebo-Controlled Studies"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H

Poster Presentation
Abstract: 480-P
Presenter: Ken Fujioka, M.D., Scripps Clinic, La Jolla, CA
Title: "Naltrexone SR/Bupropion SR Combination Therapy Improves Control of Eating and Reduces Food Cravings in Overweight/Obese Subjects"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H

Poster Presentation
Abstract: 482-P
Presenter: F. Xavier Pi-Sunyer, M.D., St. Luke's-Roosevelt Hospital and Columbia University, New York, NY
Title: "Naltrexone SR/Bupropion SR Combination Therapy Had No Effect on Depression or Suicidal Ideation: A Pooled Analysis From the Contrave Obesity Research Program"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H

Poster Presentation
Abstract: 479-P
Presenter: Raymond A. Plodkowski, M.D., University of Nevada School of Medicine, Reno, NV
Title: "COR I: Naltrexone SR/Bupropion SR Combination Therapy Reduced Weight and Improved Weight-Related Quality of Life in a Phase 3, 56-Week, Double-Blind, Placebo-Controlled Study"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H

Poster Presentation
Abstract: 481-P
Presenter: Susan L. McElroy, M.D., Lindner Center of Hope, Mason, OH
Title: "Reduced Depressive Symptoms and Weight loss in Depressed Overweight/Obese
Subjects Completing 24 Weeks of Open Label Therapy with Naltrexone SR/Bupropion SR"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H

Poster Presentation
Abstract: 499-P
Presenter: Domenica Rubino, M.D., Washington Center for Weight Management & Research, Arlington, VA
Title: "Naltrexone SR/Bupropion SR Combination (NB) Therapy Shifts Subjects From the Obese to the Non-obese Body Mass Index (BMI) Classes—From the COR-II Phase 3, Double-blind, Placebo-controlled, 56-week Study"
Time: 12:30 – 1:30 p.m. PT
Location: Hall H

 
   


 

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®. The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.

SOURCE Orexigen Therapeutics, Inc.

CONTACT: Graham Cooper of Orexigen, +1-858-875-8600; or Media, Carolyn Wang, +1-415-225-5050, or Liz Frank, +1-212-301-7216, both for Orexigen
 

Web Site: http://www.Orexigen.com
 

Posted: October 2010

View comments

Hide
(web3)